Allakos is a biotechnology company developing therapeutic antibodies for inflammatory diseases with significant unmet medical needs. Our lead program is lirentelimab (AK002), an antibody that targets Siglec-8 to selectively deplete eosinophils and inhibit mast cells. Lirentelimab has demonstrated clinical activity in eosinophilic gastritis (EG) and eosinophilic duodenitis (EoD) as well as chronic urticaria, allergic conjunctivitis, and mast cell GI disease. Currently, lirentelimab is being studied in a phase 3 study in EG and/or EoD, and a phase 2/3 study in eosinophilic esophagitis.


Hamta Podesta, PhD

We have 3 prizes for you!

• 2 Maui Jim Gift Certificates
• $500 Gift Certificate for the Allison Inn & Spa

Enter to win by clicking the entry button below and submitting your name and email address. You can enter 1 time at each vendor to improve your odds of winning. *Invalid email address entries and duplicate entries from the same showcase site will be deleted before the drawing.

Contact Allakos

Please enter your name.
Please enter a subject.
Please enter a valid phone number.
Please enter a message.